HOME > BUSINESS
BUSINESS
- Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
- Urief Authorized Generics Now Available: Daiichi Sankyo Espha
March 13, 2019
- FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
March 13, 2019
- Vadadustat Demonstrates Efficacy, Safety in 4 PIII Studies for Renal Anemia: Mitsubishi Tanabe
March 13, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Vimpat Dry Syrup Now Available: Daiichi Sankyo, UCB
March 12, 2019
- BMS, Ono Submit Additional Study Data on Orencia for Prevention of Structural Damage to Joints
March 12, 2019
- Fujifilm Toyama Chemical, Sanwa Kagaku Tie Up for Lantus Biosimilar Promotion
March 12, 2019
- UCB, Otsuka to End Copromotion Deal for E Keppra in Japan in 2020
March 12, 2019
- Daiichi Sankyo Espha Launches Authorized Iressa Generic, Introducing AI to Respond to Inquiries
March 12, 2019
- Entyvio Shows Superiority to Humira in PIIIb Study for UC: Takeda
March 12, 2019
- Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
- Japan Ethical Drug Sales Up 3.3% in January: Crecon
March 11, 2019
- CMIC CMO, Aprecia Join Hands for 3D Printing Therapies
March 11, 2019
- Eisai CEO Says “20% ROE in 2025” within Reach If All 3 Alzheimer’s Candidates, Lenvima Deliver
March 8, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
- Avastin Top Seller in Japan in February: Encise Snapshot
March 8, 2019
- Mitsubishi Tanabe’s Rupafin Most Promoted Drug in December: Anterio
March 8, 2019
- Eisai Seeks Japan Approval for Insomnia Med Lemborexant
March 8, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
